论文部分内容阅读
目的:分析慢性胃炎予雷贝拉唑和替普瑞酮联合治疗的效果。方法:回顾性分析2012年2月-2015年2月本院150例慢性胃炎患者临床资料,按不同治疗方案分为两组,对照组74例行替普瑞酮治疗,研究组76例在其基础上行雷贝拉唑治疗,观察两组疗效、胃黏膜的EGFR表达及修复效果。结果:对照组总有效率79.7%低于研究组97.4%,且EGFR表达的水平低于研究组,慢性炎症及活动性炎症评分均高于研究组,均具统计学意义(P<0.05)。结论:慢性胃炎予雷贝拉唑和替普瑞酮联合治疗的临床效果显著,值得推广。
Objective: To analyze the effect of combination therapy of rabeprazole and teprenone on chronic gastritis. Methods: The clinical data of 150 patients with chronic gastritis in our hospital from February 2012 to February 2015 were retrospectively analyzed. The patients were divided into two groups according to different treatment regimens. The control group, 74 patients treated with teprenone, the study group of 76 patients Rabeprazole was given as the basis to observe the curative effect of the two groups and the EGFR expression in gastric mucosa and its repair effect. Results: The total effective rate in the control group was 79.7% lower than that in the study group (97.4%). The level of EGFR expression in the control group was lower than that in the study group. The scores of chronic inflammation and active inflammation were both higher than those in the study group (P <0.05). Conclusion: The clinical effect of combination of rabeprazole and teprenone in chronic gastritis is significant and worthy of promotion.